Health
CSOFT’s health blog aims to provide insight into complex diseases, treatment options and regulatory developments, and other prevalent health issues people face today.
Pfizer Reaches Breakthrough Results with COVID-19 Vaccine Candidate
Based on initial trial results, Pfizer’s vaccine candidate for COVID-19 has proven to be 90% effective in fighting the virus. Pfizer and their German partner BioNTech expect a regulatory decision for emergency use authorization as soon as...
Brilanta by AstraZeneca Approved to Reduce Risk of Stroke
Brilanta was approved by the U.S. Food and Drug Administration (FDA) for its efficacy in reducing the risk of stroke in patients with acute-ischemic stroke based on the Phase 3 THALES Trial. Compared to aspirin alone, when taken with Brilanta there was a clinically...
Merck Acquires Velosbio for $2.75 Billion for Promising Cancer Therapy
Today (11/5) Merck announced their all-cash acquisition of San Diego’s VelosBio following the release of Phase 1 data of ROR1 targeting VLS-101. VLS-101 is a drug for treatment of hematologic malignancies, and exited clinical trial Phase 1 with results showing...
Biogen is Hopeful for First Alzheimer’s Drug in 20 Years to be Approved by FDA
Biogen’s aducanumab has been praised before a final approval meeting by the U.S. Food and Drug Administration (FDA) to treat the disease that is the sixth leading case of death among 65+, Alzheimer’s. Biogen is expecting “blockbuster” sales of over $1 billion from the...
First-of-its-Kind HIV Self-Test Approved by Health Canada
BioLytical Laboratories has been approved for the commercial use of their at-home HIV self-test kit that yields 99% accuracy and takes about one minute to produce results to combat the rising HIV cases in Canada. The INSTI HIV Self-Test kit is BioLytical’s newest...
FDA Approved Boston Scientific’s Ranger Balloon
The Ranger Drug-Coated Balloon was approved today (10/2) by the U.S. Food and Drug Administration (FDA) for the treatment of patients with peripheral artery disease, a disease that affects 200 million people. The disease is characterized by a plaque build up in the...
Johnson & Johnson Informs CDC of Plans to Experiment Vaccine Candidate on 12-18-Year-olds
In late September, Johnson & Johnson commenced a clinical study for their COVID-19 vaccine candidate on 60,000 adults. A company executive declared that they would start experimenting as soon as possible, and depending on results, and other factors would continue...
Planning for Translations – Where to Start?
For life science companies, understanding their business needs for translations is critical for finding the right solution. With so many different options for translation, including employing freelance translators, full-service language service providers (LSP), and...
Moderna’s Late Stage COVID-19 Vaccine on Track to Release Data Next Month
Today, (10/29) Moderna said that will release data on its experimental COVID-19 vaccine that will give insight on its efficacy. The company says they will produce 20 million doses by the end of the year. Pfizer and BioNTech are using similar technology to create their...
World Health Organization Backed by COVAX to Deliver 200 Million COVID-19 Vaccines
The COVAX initiative, worth $18 billion, is planning to administer COVID-19 vaccines to two-thirds of the world’s population by 2021. Sanofi and GalxoSmithKline have agreed to supply 2 million doses to the World Health Organization (WHO) of a vaccine they have been...
Categories
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com